Candida haemulonii complex: Species identification and antifungal susceptibility profiles of clinical isolates from Brazil

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 1, 2015, Pages 111-115

  Ramos, Lívia S ^a   Figueiredo Carvalho, Maria Helena G ^b   Barbedo, Leonardo S ^b   Ziccardi, Mariangela ^a,c   Chaves, Alessandra L S ^d   Zancopé Oliveira, Rosely M ^b   Pinto, Marcia R ^e   Sgarbi, Diana B G ^e   Dornelas Ribeiro, Marcos ^a   Branquinha, Marta H ^a   Santos, André L S ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b Funda??o Oswaldo Cruz   (Brazil)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

^d INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^e FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

Author keywords

Antifungal susceptibility; Brazilian hospitals; Candida haemulonii complex; Resistance

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; VORICONAZOLE; ANTIFUNGAL AGENT; FUNGAL DNA; RIBOSOMAL SPACER DNA;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASSAY; BIOCHEMICAL ANALYSIS; BRAZIL; BRAZILIAN; BROTH DILUTION; CANDIDA; CANDIDA DUOBUSHAEMULONII; CANDIDA HAEMULONII VAR. VULNERA; CLAVISPORA; CLINICAL ARTICLE; FUNGUS ISOLATION; GENE SEQUENCE; HUMAN; NUCLEOTIDE SEQUENCE; SPECIES IDENTIFICATION; CANDIDIASIS; CHEMISTRY; CLASSIFICATION; CLUSTER ANALYSIS; DNA SEQUENCE; DRUG EFFECTS; GENETICS; HOSPITAL; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MOLECULAR GENETICS; PHYLOGENY;

ANTIFUNGAL AGENTS; BRAZIL; CANDIDA; CANDIDIASIS; CLUSTER ANALYSIS; DNA, FUNGAL; DNA, RIBOSOMAL SPACER; HOSPITALS; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; MYCOLOGICAL TYPING TECHNIQUES; PHYLOGENY; SEQUENCE ANALYSIS, DNA;

EID: 84928328583     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku321     Document Type: Article

References (20)

1. Gargeya IB, Pruitt WR, Meyer SA et al. Candida haemulonii from clinical specimens in the USA. J Med Vet Mycol 1991; 29: 335-8.
2. Goswami R, Dadhwal V, Tejaswi S et al. Species-specific prevalence of vaginal candidiasis among patients with diabetes mellitus and its relation to their glycaemic status. J Infect 2000; 41: 162-6.
3. Ruan SY, Kuo YW, Huang CT et al. Infections due to Candida haemulonii: species identification, antifungal susceptibility and outcomes. Int J Antimicrob Agents 2010; 35: 85-8.
4. Almeida JN Jr, Motta AL, Rossi F et al. First report of a clinical isolate of Candida haemulonii in Brazil. Clinics 2012; 67: 1229-31.
5. Oberoi JK, Wattal C, Goel N et al. Non-albicans Candida species in blood stream infections in a tertiary care hospital at New Delhi, India. Indian J Med Res 2012; 136: 997-1003.
6. Kim S, Ko KS, Moon SY et al. Catheter-related candidemia caused by Candida haemulonii in a patient in long-term hospital care. J Korean Med Sci 2011; 26: 297-300.
7. Crouzet J, Sotto A, Picard E et al. A case of Candida haemulonii osteitis: clinical features, biochemical characteristics, and antifungal resistance profile. Clin Microbiol Infect 2011; 17: 1068-70.
8. Khan ZU, Al-Sweih NA, Ahmad S et al. Outbreak of fungemia among neonates caused by Candida haemulonii resistant to amphotericin B, itraconazole, and fluconazole. J Clin Microbiol 2007; 45: 2025-7.
9. Cendejas-Bueno E, Kolecka A, Alastruey-Izquierdo A et al. Reclassification of the Candida haemulonii complex as Candida haemulonii (C. haemulonii group I), C. duobushaemulonii sp. nov. (C. haemulonii group II), and C. haemulonii var. vulnera var. nov.: three multiresistant human pathogenic yeasts. J Clin Microbiol 2012; 50: 3641-51.
10. Kim M, Shin JH, Sung H et al. Candida haemulonii and closely related species at 5 university hospitals in Korea: identification, antifungal susceptibility, and clinical features. Clin Infect Dis 2009; 48: 57-61.
11. Shin JH, Kim MN, Jang SJ et al. Detection of amphotericin B resistance in Candida haemulonii and closely related species by use of the Etest, Vitek-2 yeast susceptibility system, and CLSI and EUCAST broth microdilution methods. J Clin Microbiol 2012; 50: 1852-5.
12. Lavarde V, Daniel F, Saez H et al. Peritonitemycosique a Torulopsis haemulonii. Bull Soc Fr Mycol Med 1984; 13: 173-6.
13. Sugita T, Takashima M, Poonwan N et al. Candida pseudohaemulonii sp. nov., an amphotericin B-and azole-resistant yeast species, isolated from the blood of a patient from Thailand. Microbiol Immunol 2006; 50: 469-73.
14. Satoh K, Makimura K, Hasumi Y et al. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol 2009; 53: 41-4.
15. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Third Informational Supplement M27-S3. CLSI, Wayne, PA, USA, 2008.
16. Hospenthal DR, Murray CK, Beckius ML et al. Persistence of pigment production by yeast isolates grown on CHROMagar Candida medium. J Clin Microbiol 2002; 40: 4768-70.
17. Pfaller MA, Diekema DJ, Gibbs DL et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol 2010; 48: 1366-77.
18. Xess I, Jain N, Hasan F et al. Epidemiology of candidemia in a tertiary care centre of north India: 5-year study. Infection 2007; 35: 256-9.
19. Ramos LS, Barbedo LS, Braga-Silva LA et al. Protease and phospholipase activities of Candida spp. isolated from cutaneous candidiasis. Rev Iberoam Micol 2014; doi:10.1016/j.riam.2014.01.003.
20. Pfaller MA, Woosley LN, Messer SA et al. Significance of molecular identification and antifungal susceptibility of clinically significant yeasts and moulds in a global antifungal surveillance programme. Mycopathologia 2012; 174: 259-71.